Marlborough’s Boston Scientific posted $1.964 billion in sales in its first quarter, eclipsing the company’s guidance and representing 13 percent year-over-year growth with the company poised for more product launches and growth this year, company officials announced Wednesday.
The company’s strong sales, led by 8-percent organic growth, translated into a strong profit with earnings per share of 28 cents. Sales growth was spread across the globe but grew mainly on the back of the company’s stent business.
Notable developments for the company in the quarter included approval of numerous MRI-compatable products, new stent systems and U.S. Food & Drug Administration approval of the Blazer catheter.
